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Available online 13 August 2013Two candidate preparations of human sequence recombinant Interleukin-2 (IL-2) were formulated
and lyophilized at NIBSC prior to evaluation in a collaborative study for their suitability to serve as a
replacement international standard. The preparationswere tested by eight laboratories using in vitro
bioassays and immunoassays. The candidate preparation 86/500 was judged suitable to serve as a
replacement international standard based on the data obtained for activity and stability. On the basis
of the results reported here, the preparation coded 86/500 was established by the WHO Expert
Committee on Biological Standardisation (ECBS) in 2012 as theWHO 2nd IS for human IL-2 with an
assigned value for IL-2 activity of 210 IU/ampoule. Calibration of the 2nd IS is primarily based on the
bioassay in use in various laboratories and relies exclusively on the estimates calculated relative to
the WHO 1st IS for continuity of the IU.







Interleukin-2 is approved for the treatment of metastatic
renal cell carcinoma and metastatic melanoma patients. The
complex biology of IL-2 however has meant that despite
extensive clinical trials involving IL-2 immunotherapy in various
malignancies, the therapeutic utility of IL-2 has not been realised
either due to its toxicity at high doses and/or limited efficacy.
Additionally, in HIV positive patients, IL-2 either alone or as
combination therapy with antiviral agents to boost numbers of
CD4+ T cells has not provided any significant clinical benefit.
Alternative approaches for IL-2 based immunotherapy e.g. toxinSection, Biotherapeutics
y, Blanche Lane, South
1707 641472; fax:+44
adhwa).
r B.V. Open access under CC BYconjugates, antibodies, fusion proteins, gene therapy are there-
fore currently being explored in various cancers (Eigentler et al.,
2011; Telang et al., 2011; Gubbels et al., 2011). However, since
IL-2 is essential for the development, survival and function of
regulatory T (Treg) cells, which function to inhibit immune
responses and prevent autoimmune disease, IL-2 may have a
role in promoting T cell tolerance (an important consideration is
the dose of IL-2 used as a low dose appears to favour tolerance
over autoimmunity). This has been demonstrated recently in
two early-phase clinical trials (Malek and Pugliese, 2011;
Saadoun et al., 2011; Koreth et al., 2011). In patients with
chronic graft-versus-host disease or with hepatitis C virus-
induced vasculitis, treatment with low dose IL-2, resulted in
substantial clinical improvement, which correlated with in-
creased numbers of Treg cells in these patients (Saadoun et al.,
2011; Koreth et al., 2011). Further clinical trials with suitable
dose ranges in various autoimmune indications may prove
beneficial as evidence suggests that striking the balance between
the types of cells (e.g., Tregs, T effector cells etc) that are induced
by IL-2 will be needed for effective immunotherapy with IL-2
(Malek and Pugliese, 2011). Based on this premise, trials in-NC-ND license.
2 M. Wadhwa et al. / Journal of Immunological Methods 397 (2013) 1–7diabetic patients and future directions for use of IL-2 therapy are
currently being considered (http: //clinicaltrials.gov/ct2/show/
NCT01353833; Long et al., 2013).
The 1st WHO International Standard (IS) for Interleukin-2
(IL-2) (86/504) consisting of a highly purified preparation of
glycosylated IL-2 derived from Jurkat cells (Robb et al., 1983)
was established by the WHO Expert Committee on Biological
Standardisation (ECBS) in 1987. On the basis of an interna-
tional collaborative study involving a wide range of bioassays
which predominantly used either mouse or human T
cell-lines and, in rare instances, lectin-stimulated blast cells,
the WHO 1st IS for IL-2 (coded 86/504) was assigned a
potency of 100 IU/ampoule (WHO Expert Committee on
Biological Standardisation, 1988; Gearing and Thorpe, 1988).
To date, the 1st IS for IL-2 has proved suitable for its intended
purpose, in particular, potency labelling of approved IL-2
products including Proleukin (INN Aldesleukin) the first
clinical product. Since stocks of the 1st IS are, however,
nearly exhausted, the WHO ECBS in 2011 recognized the
need for a replacement international standard for IL-2 and
agreed that lyophilized candidate preparations from the
previous collaborative study (for establishment of 1st IS) for
IL-2 should be evaluated in a study and, subject to their
suitability, be considered to serve as a potential replacement
standard.
The 1st IS for IL-2 was selected based on prevailing
opinion (over 20 years ago) that a T cell derived material
may be advantageous. However, this has not been borne out
by experience gained over the last two decades and given
that T cell derived material is no longer produced and
marketed products are E. coli expressed, it is appropriate that
the standard is prepared using E. coli expressed material.
Furthermore, it has been shown that glycosylation of IL-2
does not affect its biological activity (Robb et al., 1984;
Koichi, 1988). On the basis of this rationale, we evaluated in a
multi-centre international collaborative study, two candidate
IL-2 preparations, both expressed in E. coli, with the main
objective of selecting and characterizing a suitable WHO 2nd
IS (for replacement for the 1st IS) for the bioassay of human
IL-2 and assigning a unitage of IL-2 activity. To achieve this,
the study sought to assess the biological activity and the
suitability of ampouled lyophilized preparations of human
Interleukin-2 (IL-2) to serve as 2nd IS for human IL-2 by
assaying their biological activity in routine, “in-house”
bioassays currently in use in different laboratories and to
calibrate the candidate preparations against the 1st IS (86/
504). Calibration of the WHO 2nd IS is therefore, primarily
based on the bioassay in use in various laboratories and reliesTable 1
Materials used in study.
Ampoule code Study code Ampoule contents
IL-2
(Predicted Mass - ng)
Sour
86/500 A, B 15.3 E. co
86/564* C 15.3 E. co
89/668** D – E. co
86/504 Current IS 7.6 Jurk
HSA - Human serum albumin; * - IL-2 mutein, cysteine at position 125 replaced withentirely on the estimates calculated relative to the WHO 1st
IS for continuity of the IU.
2. Materials and methods
Two preparations of recombinant human sequence IL-2
expressed in E coli kindly donated toWHO (see Acknowledge-
ment) were evaluated in the study. These preparations were
originally included in the previous collaborative study for
establishment of 1st IS for IL-2 (86/504) and were lyophilized
into ampoules at NIBSC in 1986 as per the procedures used
previously for International Biological Standards (WHO
Technical Report Series, 1978).
Buffers, final compositions as shown in Table 2, were
prepared using nonpyrogenic water and depyrogenated glass-
ware. Buffer solutions were filtered using sterile nonpyrogenic
filters where appropriate. Further details regarding these
preparations have been previously published (Gearing and
Thorpe, 1988).
For the study, the two rDNA derived preparations were
coded as described in Table 2. The mass content of the
preparations was determined by the manufacturers. As the
protein content of the ampoules cannot be verified by direct
measurement of absolute mass, the content is assumed to be
the theoretical mass, calculated from the dilution of the bulk
material of known protein mass content, and the volume of
formulated solution delivered to the ampoule. This mass
value is given as “predicted ng”.
For all preparations, the appropriate volume was added to
the buffer to give 2.0 (±1%) l of a solution of IL-2 which was
then distributed in 0.5 ml aliquots, giving the theoretical
protein content per ampoule as shown in Table 1.
For each fill, a percentage of ampoules were weighed. The
mean fill weights were 0.5058 g for 86/500 (n = 72), 0.5042 g
for 86/564 (n = 69) and 0.5064 (n = 70) for the 1st IS. The
precision of filling of ampoules had a CV in the range of 0.098 –
0.257% as assessed by determination of mean fill weights for all
preparations. Each solution was lyophilized, and the ampoules
were sealed under dry nitrogen by heat fusion of the glass and
stored at –20 °C in the dark. The mean residual moisture of all
preparations, measured by the coulometric Karl-Fischer meth-
od (Mitsubishi CA100), varied between 0.038 and 0.104%.
Mean headspace oxygen content determined by frequency
modulated spectroscopy using the Lighthouse FMS-760 Instru-
ment (Lighthouse Instruments, LLC) varied from 0.28 to 0.84%
for all preparations. Testing for microbial contamination using
Total viable count method did not show any evidence of
microbial contamination.ce Excipients
li 1% HSA, 0.5% Trehalose, RPMI 1640
li 1% HSA, 0.5% Trehalose, Phosphate Buffered Saline
li 0.2% HSA, 0.1% Trehalose, 0.9%NaCl
at cell derived 1% HSA, 0.5% Trehalose, Phosphate Buffered Saline
alanine, ** - an irrelevant preparation containing rDNA derived human IL-4.
Table 3




7 Multiarray and Multispot ECL: IL-2 ultrasensitive kit
1Ba Commercial ELISA
6Ba ELISA (Quantikine)
6C Fluorokine Map Cytokine Multiplex Human IL-2
a Different commercial ELISAs were used by laboratories 1B and 6B.
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Eight participants from four countries contributed data to
the study. These comprised 2 control laboratories, 5 manu-
facturers' laboratories and 2 regulators and are listed. In this
report, each laboratory has been identified by a number from
1 to 8 that is not related to this order of listing.
• Cheryl Gurecki and Rosanne Carey, Bayer Healthcare Phar-
maceutical Inc, Emeryville Supply Center,4225 Horton Street,
94608 Emeryville, CA, USA.
• Scott Craig, Biochemistry, Office of Laboratories and Scientific
Services (OLSS), TGA, 136 Narrabundah Lane, Symonston
ACT 2609, Australia.
• GuopingWu, John Beauchamp and Aaron Boeckermann, R&D
Systems Inc, 614McKinley Place, NEMinneapolis, MN 55413,
USA.
• Chris Bird and Paula Dilger, Cytokines and Growth Factors
Section, Biotherapeutics Group, NIBSC.
• Yang Meihua, Xiamen Amoytop Biotech Co., No.330 Wengjiao
Road, Haicang, Xiamen, Fujian, P.R. China 361022.
• Gao Kai and Pei DeNing, Division of Biopharmaceuticals,
NIFDC, NO2. Tiantan Xili, Beijing 100050, P.R. China.
• Baozhu Shao, Shenyang sunshine pharmaceutical Co Ltd, No.
3A1, road 10, Econ & Tech Development Zone, Shenyang, P.R.
China, 110027.
• Pankaj Oberoi and Joseph C.Manimala,Meso Scale Discovery,
9238 Gaither Rd, Gaithersburg, MD 20877.2.2. Assay methods and study design
A brief summary of the assay methods used in the study is
given in Table 2. Most bioassays measured the proliferative
effect of IL-2 on the murine cytotoxic T cell-line, CTLL-2 or the
HT-2 cell-line but employed different readouts for assessing
the proliferation (Gillis et al., 1978; Gieni et al., 1995). In one
laboratory, however, the human T cell-line, KIT 225 was used
(Hori et al., 1987). Immunoassays using commercially available
reagents/kits were also performed in three laboratories
(Table 3).
Participants were asked to assay all samples including the
current IS (86/504) concurrently on a minimum of three
separate occasions using their own routine bioassay methods
within a specified layout which allocated the samples across
5 plates and allowed testing of replicates as per the study
protocol. It was requested that participants perform eight
dilutions of each preparation using freshly reconstitutedTable 2









2 HT-2 48 Colorimetric/MTT
1A CTLL-2 24 3H Thymidine incorporation
3 CTLL-2 48 Colorimetric/MTT
6A CTLL-2 48 Fluorescence/Resazurin
5 CTLL-2 48 Colorimetric/MTT
4 KIT225/K6 48 Fluorescence/Alamar Blue
8 CTLL-2 56 Colorimetric/MTT
⁎ ⁎HT-2 and CTLL-2 - murine; KIT-225 - human.ampoules for each assay. Where available they were asked to
include their own in-house reference material.
Participants were sent study samples coded A–D along
with the current IS (86/504) and a sample of an irrelevant
preparation, coded D as detailed in Table 1. Samples A and B
were coded duplicate samples of the same material (candidate
replacement standard 86/500). Participants were requested to
return their raw assay data, using spreadsheet templates
provided.
All laboratories are referred to by a code number, allocated at
random, and not representing the order of listing in the
appendix. Where a laboratory returned data from more than
one method, the different assay methods were analysed and
reported separately and coded, for example, laboratories 1A and
1B.
2.3. Statistical methods
The potencies of the study samples were calculated relative
to the current IS (86/504) by analysis of the raw assay data at
NIBSC. A parallel-line approach was used, fitting 4-parameter
sigmoid curves with the European Directorate for Quality of
Medicines and Healthcare (EDQM) assay analysis software,
CombiStats (http://combistats.edqm.eu/). The usual analysis of
variance tests of parallelism or linearity were applied, along
with visual inspection of the plotted data, to assess the
suitability of the model fit. Where a “hook” effect (drop in
response at high concentrations) was observed, the relevant
responses were excluded from the analysis. Where necessary,
some low responses close to backgroundwere also excluded. In
some cases it was not possible to fit the sigmoid model, and
analysis was based on a restricted straight-line section of the
log transformed dose–response (Finney, 1978). Where assays
were split over several individual plates, each plate was
analysed separately, and a single potency estimate for each
sample was calculated as the unweighted geometric mean
across all plates.
Potencies within laboratories were combined using
unweighted geometric means, and intra-laboratory variabil-
ity was expressed as geometric coefficients of variation
(%GCV) (Kirkwood, 1979). Overall potencies were calculated
as geometric means of the individual laboratory means, and
inter-laboratory variability was expressed as %GCVs between
laboratory means.
The agreement between duplicate samples was assessed by
calculating the difference in log potency estimates (relative to
86/504) of samples A and B for each assay, calculating themean
of the squared difference for each laboratory, taking the square
root to give a root mean square (RMS) value, and expressing
this as an average percentage difference.
Table 4
Laboratory mean potencies relative to current is 86/504 (=100 IU).
Laboratory Method Sample
A B C
Potency % GCV Potency % GCV Potency % GCV
1A B 194 4.4 194 7.3 244 4.9
1B E 218 2.0 219 0.8 239 3.3
2 B 243 2.7 253 3.9 250 0.7
3 B 208 5.5 216 6.9 237 3.6
5 B 227 3.9 222 4.8 242 4.5
6A B 183 5.2 187 4.3 259 3.1
6B E 198 0.8 202 1.4 237 1.6
6C M 185 2.9 188 0.5 251 6.1
7 ECL 158 4.1 156 4.5 182 4.2
8 B 211 6.1 209 3.9 233 2.0




B - bioassay, E - ELISA, M - Multiplex, ECL - Electrochemiluminescence assay.
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Samples of the candidate standard 86/500 (coded A & B)
stored at elevated temperatures (4 °C and 20 °C) for 26 years
and 1 month were tested concurrently with those stored at the
recommended storage temperature of −20 °C, and baseline
samples stored at −70 °C. Samples had also been stored at
+37 °C but it was not possible to properly reconstitute these
samples after such a long period at high temperature. Four
independent assays were performed and each assay replicated
over three plates. The assays were analysed as described for the
main collaborative study, and the potencies of all samples were
expressed relative to the baseline samples stored at−70 °C.
In addition, the stability of the samples at 4 °C and 20 °C
after periods of 4 h, 24 h and 1 week following reconstitution
and after a series of freeze–thaw cycles (1 up to 4)was assessed
relative to the freshly reconstituted sample. The assays were
analysed as described for the main collaborative study, and the
potencies of the stored samples were expressed relative to the
freshly reconstituted sample. All studies were conducted at
NIBSC using the CTLL-2 cell-line-based bioassay.Table 5
Average % difference in potencies between samples A












While a majority of participants (Hori et al., 1987)
performed bioassays (Table 2), two participants also
performed immunoassays (laboratories 1 and 6) as shown
in Table 3. All participating laboratories returned data from at
least three independent assays, each with multiple plates.
Only some responses at the highest and lowest concentra-
tions in individual assays (hook effect and background) were
excluded from the analysis. Since data from laboratory 4
exhibited a limited dose–response over a narrow dilution
range, with high variability and high background levels, it
was not possible to apply the parallel line sigmoid model to
this data and results from this laboratory were not included.
In total, statistical analysis included six data sets from
bioassays and four from immunoassays.3.1. Potencies of samples A–D relative to 1st IS (coded 86/504)
Sample D, containing rDNA-derived human IL-4, did not
give a dose–response in any of the assays, and was not
included in subsequent analysis.
The laboratory mean potencies for samples A – C relative to
the current IS 86/504 are shown in Table 4. The values shown
are in IU, based on the assigned value of 100 IU for 86/504.
From Table 4, it is evident that the immunoassays from
laboratory 7 are giving lower estimated potencies for all three
samples A – C. Laboratory 2 has estimates that are higher than
other laboratories for samples A and B, but for sample C they
are in agreement with the other laboratories. Apart from these
results, all laboratories appear to be giving consistent results
and are in reasonable agreement.
The within-laboratory, between-assay, variability is shown
in Table 4, as %GCVs. These represent good within laboratory
repeatability, with all GCVs less than 10%, and the majority
being less than 5%. There was greater variability between
estimates from individual plates within assays in some
laboratories (data not shown). This appeared to result from
possible plate effects (variation in response across different
rows or columns of the plate). Because a balanced layout was
used, varying the position of the samples across different
Table 7
Overall means and between laboratory %GCV based on bioassay data only.
Sample n Mean %GCV Min Max
A 6 210 10.9 183 243
B 6 212 11.2 187 253
C 6 244 3.8 233 259
Table 8
Laboratory mean potencies of sample C relative to sample A (=200 IU).
Sample C relative to A
Laboratory Potency (IU) %GCV
1A 251 2.5
5M. Wadhwa et al. / Journal of Immunological Methods 397 (2013) 1–7plates, consistent results were obtained when the individual
plate estimates were combined to give single assay estimates.
However, it does emphasise the need to be aware of potential
plate effects, and the importance of using a suitable experi-
mental layout across plates.
Samples A and B are duplicates of the same material (86/
500). The average within-assay % differences in potency
estimates between duplicates are shown in Table 5. All but
one of the laboratories are achieving average agreement
within 10%, with the majority being within 5%. The overall
geometric means of the laboratory means, along with
between-laboratory %GCVs and the range of potency esti-
mates are shown in Table 4.
The overall trimmed mean (excluding the highest and
lowest laboratory estimates) are shown in Table 6. For the
candidate standard 86/500, there is very little difference
between the overall mean and the trimmed mean. The effects
of the low results from laboratory 7 and the high results from
laboratory 2 on the overall mean cancel each other out. The
combined overall mean for samples A and B is 202 IU based on
all laboratories, or 203 IU based on the trimmed mean of the
central 8 laboratories. For sample C, the potency estimates are
around 20% higher than for A and B, at 236 IU and 242 IU for
the overall and trimmed means respectively.
Table 7 shows the overall means based on the 6 laboratories
performing bioassay only. For the candidate standard 86/500
the mean is a little higher at 211 IU compared to the 201 or
203 IU from the overall or trimmed means of all laboratories.
This is because restricting the calculation to the bioassays alone
has the effect of removing the low results from the immuno-
assay of laboratory 7, but including the high results from the
bioassay of laboratory 2. For sample C, there is little difference
between the trimmed mean of all laboratories and the overall
mean of the bioassays alone. As noted above, the estimates
from laboratory 2 for sample C are consistent with those from
other laboratories.
The overall potency estimate of the candidate standard
86/500 based on the laboratories performing bioassays is
211.3 IU, with 95% confidence interval from 189.4 to
235.7 IU.
Samples A and B (86/500) and sample C (86/564) were all
included in the original collaborative study that was
conducted to establish the 1st IS 86/504 (Kirkwood, 1979).
Based on the data presented in that study, the estimated
potency of 86/500 relative to 86/504 was 204 IU, in excellent
agreement with the results from the current study, and
providing further evidence of the long-term stability of 86/
500. The potency of 86/564 relative to 86/504 in the original
study was 225 IU, in reasonable agreement with the results
from the current study.Table 6
Overall trimmed means and between laboratory %GCV excluding highest
and lowest laboratory estimates.
Sample n Mean %GCV Min Max
A 8 202 8.0 183 227
B 8 204 7.0 187 222
C 8 242 2.6 233 2513.2. Potency of sample C (86/564) relative to sample A (86/500)
The potency of sample C (86/564) was also calculated
relative to sample A (86/500), the candidate replacement IS,
assuming a hypothetical value of 200 IU for 86/500. These
calculations were performed for each assay, and the laboratory
means, within-laboratory between-assay %GCVs, and overall
means, were calculated in the same way as for potencies
relative to 86/504 above.
The individual laboratory mean estimates are shown in
Table 8, along with the within laboratory %GCVs. The overall
mean estimate, and between-laboratory %GCV, are also
shown in Table 8. The overall mean is 235 IU, consistent
with the overall mean of 236 IU calculated relative to 86/504
(Table 4). The between laboratory and within laboratory
variation, as measured by the %GCVs, are comparable to the
values obtained for sample C relative to 86/504.
3.3. Stability studies
For this, samples of 86/500 stored at−70 °C,−20 °C,+4 °C
and+20 °C were assayed, subsequently analysed and potencies
expressed relative to the samples stored at −70 °C. The mean
potency estimates of the candidate A (coded 86/500) stored at
different temperatures (expressed as a percentage of the−70 °C
sample) are shown in Table 9. There is no detectable degrada-
tion, even after 26 years at+20 °C. It is not possible to apply the
usual Arrheniusmodel to obtain predictions of % loss per year, as
there is no degradation. Clearly 86/500 is very stable, and
suitable to serve as a standard.
Although samples had also been stored at+37 °C, it was not
possible to properly reconstitute these samples after such a long
period at high temperature. Therefore, to confirm the stability










Overall mean (n = 10) 235
Between laboratory %GCV 11. 0
Table 9
Overall unweighted geometric mean potencies (%) of samples stored at
elevated temperatures relative to the −70 °C sample.




6 M. Wadhwa et al. / Journal of Immunological Methods 397 (2013) 1–7had been stored for 1 month at +37 °C, and this was
indistinguishable from the−20 °C sample (data not shown).
Further studies showed that the potency of 86/500 is not
diminished after 1 week of storage at either +4 °C or +20 °C
following reconstitution. However, it is recommended that 86/
500 is used soon after reconstitution. Additionally, we found no
pattern of increased loss of bioactivity after subjecting the
reconstituted contents of the ampoule to increasing numbers
of freeze–thaw cycles, and with a mean potency of 98% of a
freshly reconstituted sample after four freeze–thaw cycles, 86/
500 appears highly stable. These studies suggest that the
preparation is sufficiently stable to serve as an International
standard.4. Discussion
Results derived from this study clearly demonstrate that
generally there is good agreement between the laboratories
irrespective of the assays used. There was good within
laboratory repeatability, with all GCVs less than 10%, and
the majority being less than 5%. For the duplicate samples A
and B (coded 86/500), the results were very consistent as
potency estimates in a majority of laboratories were within
5% (Table 5). Themean overall potency relative to the current
IS (coded 86/504) for duplicates A and B of the candidate
standard derived using data from all assays were 201 and
203 IU while those from bioassay alone were slightly higher
at 210 and 212 IU respectively (Tables 4 and 7).
Most laboratories performed bioassays based on the
ability of IL-2 to induce proliferation of murine T cell-lines,
CTLL-2 or HT-2 (using either a radioactive label or colorimetric/
fluorescence dye for detection) although in some laboratories,
immunoassays were also conducted. For the bioassays used in
the study, data was generally consistent and demonstrated a
low intra-laboratory and inter-laboratory variability.
For all laboratories, the potencies for samples A and B were
predominantly clustered around a value of 183–253 (relative
to current IS, 86/504). For samples A and B the intra-laboratory
variability, as measured by the within-laboratory % GCV, for all
laboratories was less than 10%, and themajority were less than
5%. The inter-laboratory variability for bioassays was less than
12% and the mean value for samples A and B based on the 6
laboratories performing bioassays is 210 and 212 IU respec-
tively with an overall mean value of 211 IU as shown in Table 7.
For the candidate standard 86/500, therefore, the mean
value from bioassay data is 211 IU which is slightly higher
compared with the 201 or 203 IU from the overall means of
assays including immunoassays from all laboratories. This is
because if considering bioassays alone, the high results from
the bioassay of laboratory 2 are included while lower valuesobtained in the immunoassay of laboratory 7 (evident for all
samples) are excluded. However, since data from bioassays in
this study is largely consistent between the different
laboratories and given that the potency of the current IS
was derived on the basis of bioassays in the previous study, it
was reasonable to assign the potency for the candidate
preparation, 86/500 using the mean from bioassays alone.
For sample C (86/564), the potency estimates while being
consistent among the different laboratories are approximately
20% higher than samples A andB (coded 86/500) relative to the
current IS; the overall mean is 236 IU.
Both candidate preparations (86/500; 86/564) were in-
cluded in the original collaborative study thatwas conducted to
establish the 1st IS 86/504 (Gearing and Thorpe, 1988). The
potency of 86/564 relative to 86/504 in the original study was
225 IU, in reasonable agreement with the results from the
current study. From data presented in the previous study, the
estimated potency of 86/500 to 86/504was 204 IU, in excellent
agreement with the results from the current study (conducted
after 25 years), and providing further evidence of the
long-term stability of 86/500. This was further confirmed by
undertaking stability studies described in this report. These
results clearly indicate that candidate preparation (code 86/
500) is highly stable and suitable for use as the 2nd
international standard for IL-2. It is therefore proposed that a
value of 210 IU/ampoule is assigned to the candidate 2nd
international standard for IL-2 in continuity with the units
assigned to the current IS for IL-2.
5. Conclusions and proposal
Based on the results of this study, the IL-2 candidate
preparation (coded 86/500) was judged to be suitable to
serve as the WHO 2nd IS for IL-2 for assessing potency of
current IL-2 therapeutic products as well as for use in
immunoassays. It was therefore, established by the WHO
ECBS as the WHO 2nd IS for IL-2 with an assigned value for
IL-2 activity of 210 IU/ampoule.
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